Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
The FDA and American Academy of Dermatology both highlight serious health risks connected to the use of compounded injectable glutathione
What is new are the specific dates (June 2024 injury, November 2024 BPC-157, nothing since), the confirmation that he has stopped TRT and has unused prescription doses sitting at home, and the disclosure that USADA has been in contact
Do not change dose or schedule without clinician approval